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Abstract 
A highly rigid open-chain octadentate ligand (H4cddadpa) containing a diaminocylohexane unit to replace 
the ethylenediamine bridge of 6,6′-[(ethane-1,2 diylbis{(carboxymethyl)azanediyl})bis(methylene)] 
dipicolinic acid (H4octapa) was synthesized. This structural modification improves the thermodynamic 
stability of the Gd
3+
 complex slightly (log KGdL=20.68 vs. 20.23 for [Gd(octapa)]
−
) while other MRI-relevant 
parameters remain unaffected (one coordinated water molecule; relaxivity r1=5.73 mm
−1 s−1 at 20 MHz and 
295 K). Kinetic inertness is improved by the rigidifying effect of the diaminocylohexane unit in the ligand 
skeleton (half-life of dissociation for physiological conditions is 6 orders of magnitude higher for 
[Gd(cddadpa)]
−
 (t1/2=1.49×10
5
 h) than for [Gd(octapa)]
−
. The kinetic inertness of this novel chelate is 
superior by 2–3 orders of magnitude compared to non-macrocyclic MRI contrast agents approved for clinical 
use. 
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Introduction 
The application of gadolinium(III) complexes as contrast agents in magnetic resonance imaging (MRI) 
requires stable complexation of the metal ion under physiological conditions to avoid the release of the toxic 
 
 
free metal ion.
[1, 2]
 Several pathways leading to the potential dissociation of Gd
3+
 complexes in vivo have 
been identified: 1) acid-catalyzed dissociation, which is often responsible for the dissociation of complexes 
with macrocyclic ligands such as dota
4−
 (Scheme 1);
[3]
 2) dissociation catalyzed by endogenous metal ions 
such as Zn
2+
 and Cu
2+
, which contributes to the dissociation of contrast agents with non-macrocyclic ligands 
such as dtpa
5−
;
[4] 
and 3) dissociation assisted by endogenous ligands like citrate, phosphate or bicarbonate, 
which is also important for non-macrocyclic contrast agents.
[5] 
Complexes of linear ligands generally present 
faster dissociation kinetics than the macrocyclic counterparts, although some macrocyclic Gd
3+
 complexes 
were shown to undergo rather fast dissociation.
[6] 
Low basicity of the Gd
3+
 complex has been identified as an 
important factor to improve its kinetic inertness. For instance, dota-tetraamide Gd
3+
 complexes were shown 
to be considerably more inert than [Gd(dota)]
−
, which has been attributed to the low basicity of the amide 
oxygen atom that makes proton transfer to the ring nitrogen very unlikely.
[7] 
Another important factor is 
rigidity, which is likely responsible for the higher kinetic inertness of macrocyclic complexes. For instance, 
cdta
4−
, which contains a rigid diaminocylohexane unit, forms considerably more inert Ln
3+
 and 
Mn
2+
complexes than the edta
4−
 analogues.
[8, 9] 
The rigidity of the backbone in numerous bishydrated 
Gd
3+
complexes of ligands derived from cdta
4−
 and 2,6-bis(aminomethyl)pyridine was also found to play an 
important role; however these systems were either similar or just slightly better than the non-macrocyclic 
MRI contrast agents available in the market.
[10, 11] 
The beneficial effect of alpha-C-substitution on the 
thermodynamic and kinetic properties of Y
3+
 complexes (Y
3+
 behaves very similarly to Gd
3+
) formed with 
dtpa-like ligands is also well documented.
[12] 
On the other hand, a rigid cross-bridge macrocyclic ligand was 
recently shown to provide exceptionally inert Ln
3+
 complexes, highlighting again the impact of ligand 
rigidity on the kinetic inertness of macrocyclic complexes as well.
[13] 
 
 
Scheme 1. Ligands discussed in the present work. 
 
 
The non-macrocyclic octadentate ligand 6,6′-[(ethane-1,2-diylbis{(carboxymethyl)azanediyl})bis 
(methylene)]dipicolinic acid (H4octapa, Scheme 1) forms Ln
3+
complexes with high thermodynamic stability 
(log K=19.9–20.5 depending on the Ln3+ ion).[14, 15] Furthermore, [Gd(octapa)]− contains a coordinated water 
molecule that results in 
1
H relaxivities similar to those of commercially available contrast agents, such as 
[Gd(dota)]
−
 or [Gd(dtpa)]
2−
.
[16]
 However, kinetic studies showed that [Gd(octapa)]
−
 is considerably more 
labile than the edta
4−
 and dtpa
5−
counterparts, which is unacceptable for practical applications.
[15]
 Herein, we 
report the octadentate ligand H4cddadpa, which incorporates a rigid diaminocyclohexane unit instead of the 
ethylenediamine linker of H4octapa. The corresponding Gd
3+
 complex retains a coordinated water molecule 
while providing improved relaxivities and thermodynamic stability with respect to [Gd(octapa)]
−
. Most 
importantly, [Gd(cddadpa)]
−
 displays an unprecedented kinetic inertness for an open-chain system. 
Ligand H4cddadpa was synthetized in four steps starting from methyl 6-formylpicolinate (1), which was 
obtained in three steps from commercially available pyridine-2,6-dicarboxylic acid.
[15]
 Reaction of 1with 
(1R,2R)-diaminocylohexane gave Schiff base 2, which was reduced with NaBH4 to give amine 3(Scheme 
2). N-alkylation of 3 with tert-butyl-2-bromoacetate at room temperature in acetonitrile solution and 
subsequent deprotection of the methyl and tert-butyl esters with 6 m HCl gave the H4cddadpa ligand, which 
was isolated with an overall yield of 37 % over the four steps (the experimental details of synthesis 
of 2 and 3 are included in the Supporting Information). The [Ln(cddadpa)]
−
 complexes (Ln=Eu or Gd) were 
prepared in aqueous solution by reaction of equimolar amounts of the ligand and Ln(OTf)3 followed by 
adjustment of the pH to about 7 with aqueous NaOH. The HR-ESI
−
 mass spectra of the complexes present a 
peak due to the [Ln(cddadpa)]
−
 entities that confirms the formation of the complexes (Figure S5 and S6, 
Supporting Information). The absorption and CD spectra of the Gd complex confirm the formation of the 
optically active complex (Figure S7, Supporting Information). 
 
 
Scheme 2. Synthesis of H4cddadpa. Reagents and conditions: i) MeOH, reflux, 4 h, 84 %; ii) NaBH4, MeOH, 91 %; iii) 
tert-butyl-2-bromoacetate (2.1 equiv), K2CO3, acetonitrile, room temperature, 4 d and 45 °C, 3 d, 65 %; iv) 6 m HCl, 
reflux, 24 h, 75 %. See the Supporting Information for experimental details. 
 
 
Equilibrium studies to obtain the ligand protonation constants and the stability constant of the Gd
3+
complex 
were carried out by pH-potentiometry (Figure S8 and S9, Supporting Information). The first protonation 
constant (Table 1) of cddadpa
4−
 is ca. 0.8 log K unit higher than that of the related octapa
4−
.
[15] 
The small 
differences in the basicity of these ligands may be attributed to the structural rigidity brought by the 
cyclohexyl bridge compared to the more flexible ethylene bridging unit. A similar increase in the basicity of 
the nitrogen atom was also observed for cdta
4−
 when comparing its log K1
H
value to that of edta
4−
.
[17]
 Similar 
to the [Gd(octapa)]
−
 complex, it was not possible to determine the stability constant of [Gd(cddadpa)]
−
 by 
using solely pH potentiometry, as the complex is nearly quantitatively formed even at pH 1.8. Therefore, the 
pH potentiometric titration data were complemented by 
1
H relaxometric titrations (the relaxivity pH profile is 
included in the Supporting Information). The relaxivity of [Gd(cddadpa)]
−
 remains constant in the pH range 
of about 12.0–2.0, and increases below about 2.0 due to the dissociation of the complex (Figure S9, 
Supporting Information). By knowing the relaxivities of the Gd
3+
 aqua ion and [Gd(cddadpa)]
−
, the stability 
constant of the complex could be determined (Table 1). Owing to the increased basicity of cddadpa
4−
, the 
stability of its Gd
3+
 complex is increased by ca 0.4 log K units in comparison to [Gd(octapa)]− and it is close 
to that of [Gd(dtpa)]
2−
 (Table 1), which is a commercial open-chain MRI contrast agent used in clinical 
practice.
[18]
 Moreover, the stability of [Gd(cddadpa)]
−
 is comparable to or slightly lower than those of the 
Gd
3+
complexes formed with macrocyclic do3a
3−
 and its derivatives used as commercial contrast agents (hp-
do3a
3−
 and do3a-butrol
3−
).
[19]
 Given the considerably lower basicity of cddadpa
4−
, the conditional stability 
constant of [Gd(cddadpa)]
−
 will be higher near physiological conditions, despite the comparable stability 
constants of the complexes. This is demonstrated by comparing the pGd values calculated as proposed by 
Raymond and co-workers (Table 1).
[20]
 The pGd value obtained for [Gd(cddadpa)]
−
 is slightly higher than 
that determined for [Gd(dtpa)]
2−
 (the increase is only 0.2 pGd units) but clearly higher than those of 
complexes with macrocyclic ligands such as [Gd(do3a)] (ca. 3.8 pGd units). This confirms that 
[Gd(cddadpa)]
−
 has the highest stability among the complexes compared in Table 1 at physiological pH. 
 
Table 1. Protonation constants of cddadpa
4−
 and related ligands and stability constants and pGd values of their 
Gd
3+
 complexes (25 °C, 0.15 m NaCl). 
 
 cddadpa
4−
 octapa
4−[a]
 dtpa
5−[b]
 do3a
3−[c,d]
 
log K1
H
 9.35(2) 8.52 9.93 11.99 
log K2
H
 5.66(3) 5.40 8.37 9.51 
log K3
H
 4.20(3) 3.65 4.18 4.31 
log K4
H
 3.72(3) 2.97 2.71 3.63 
log K5
H
 2.62(4) 1.66 2.00 1.84 
∑log Ki
H
 25.55 22.20 27.19 31.26 
log KGdL 20.68(9)
[e]
 20.23
[f]
 22.03 21.56 
log KGdHL 2.38(2)
[e]
 – 1.96 – 
pGd 19.66 19.23 19.44 15.81 
 
[a] Ref. [15]. [b] Ref. [18]. [c] Ref. [21]. [d] Protonation and stability constants were determined by using 
0.1 m KCl ionic strength. All these constants are expected to be considerably lower in 0.15 m NaCl, but the 
pGd value will be very likely similar to the one calculated by using the data corresponding to 0.1 m KCl 
ionic strength. [e] Determined by simultaneous fitting of relaxometric and pH potentiometric data. [f] 
Determined by relaxometric titration. 
 
 
Kinetic inertness is a key parameter for safe application of a Gd
3+
 complex as a contrast agent, since the 
complexes injected to the body must remain intact. In the light of the encouraging stability data discussed 
above, the kinetic inertness of [Gd(cddadpa)]
−
 was characterized by studying the rate of the metal exchange 
 
 
reaction occurring with Cu
2+
. Cu
2+
 is typically the most efficient among the physiologically relevant metal 
ions to promote transmetalation reactions with Gd
3+
 complexes.
[4, 5]
 The pseudo-first-order rate constants 
determined for the exchange reaction between [Gd(cddadpa)]
−
and Cu
2+
 ion are shown in Figure 1. 
The kobs values increase with increasing concentrations of both H
+
and Cu
2+
 ions, which can be rationalized 
by considering three dissociation pathways: spontaneous, proton-assisted (via the formation of a protonated 
[GdH(cddadpa)] intermediate) and metal-assisted (through the formation of a dinuclear reaction 
intermediate). These dissociation pathways are characterized by rate constants k0 [s
−1
], k1 [m
−1
 s
−1
], 
and k3 [m
−1
 s
−1
], respectively. The overall map of dissociation pathways, the expression used for the pseudo-
first-order rate constant (kobs) and the equations employed for data refinement are included in the Supporting 
Information. 
 
Figure 1. Plot of the pseudo-first-order rate constants measured as function of Cu
2+
 ion concentration and pH (50 
mm DMP, 25 °C, 0.15 M NaCl, pH 3.38, 3.51, 3.70, 3.96, 4.21, 4.64 and 4.94 downwards). 
 
The rate constants are compared with those of the Gd
3+
 complexes formed with octapa
4−
, dtpa
5−
, and 
do3a
3−
 in Table 2. The rate constant of the proton-assisted dissociation (k1) of [Gd(cddadpa)]
−
decreases by 
nearly three orders of magnitude when compared to the corresponding value for [Gd(octapa)]
−
. Moreover, k1 
is more than 30 times smaller for [Gd(cddadpa)]
−
 than that for [Gd(dtpa)]
2−
, and very similar to that of 
[Gd(do3a)]. On the other hand, the rate constant characterizing the direct attack of the Cu
2+
 ion on the 
complex, k3, is more than three orders of magnitude smaller for [Gd(cddadpa)]
−
 than for [Gd(dtpa)]
2−
 
(endogenous metal ions are known not to affect the dissociation of Ln
3+
 complexes of do3a
3−
 or dota
4− 
ligands).
[19] 
A comparison of the dissociation half-lives, t1/2, calculated near physiological conditions (pH 7.4, 
cCu2+=1 μm; Table 2) confirms the remarkable kinetic inertness of [Gd(cddadpa)]
−
, which results from the 
integration of a highly rigid diaminocyclohexane unit in the ligand skeleton. The deceleration of the 
dissociation is a consequence of the strained structure of the chelate, as demetalation requires structural 
rearrangements that will proceed more slowly for complexes with non-flexible ligands.
[10-12, 22] 
Indeed, the 
1
H 
NMR spectrum of the [Eu(cddadpa)]
−
 complex recorded in D2O solution shows a very rigid structure (Figure 
2). A total of 22 paramagnetically shifted signals in the range circa +28 to −14 ppm are observed (at 25 °C), 
which corresponds to a C1 symmetry of the complex. This is in contrast with the more flexible structure of 
[Ln(octapa)]
−
 complexes (Ln=La, Ce, Pr, Nd, or Sm) reflected by an effective C2 symmetry.
[16]
 
 
 
Table 2. Rate and equilibrium constants characterizing the dissociation of the Gd
3+
 complexes of cddadpa
4−
,  
octapa
4−
, dtpa
5−
, and do3a
3−
 (25 °C). 
 
 cddadpa
4−
 octapa
4−[a]
 dtpa
5−[b]
 do3a
3−[c]
 
k1 (M
−1
 s
−1
) 0.016±0.002 11.8 0.58 0.023, 0.025
[f]
 
k2 (M
−2
 s
−1
) – 2.5×104 9.7×104 – 
k3
Cu
 (M
−1
 s
−1
) 6.8±0.4×10
−4
 22.5 0.93 – 
k6
Cu
 (M
−2 s−1) – 5.0×109 – – 
KH
[d]
 737±435 398 100 – 
KCuGdL 48±8 – 13 – 
t1/2 (h)
[e]
 1.49×10
5
 0.15 202 2.10×10
5
, 
1.93×10
5[f]
 
 
[a] Ref. [15]. [b] Ref. [4]. [c] Ref. [21]. [d] A log KH value of 2.38(2) was determined by pH-potentiometry. 
[e] t1/2=ln2/kobs where kobs was calculated by using pH 7.4 and cCu2+=1 μm. [f] Ref. [23]. 
 
 
 
 
Figure 2. 
1
H NMR spectrum of [Eu(cddadpa)]
−
 recorded in D2O solution [300 MHz, 25 °C, pD 7.0]. 
 
The emission spectra of [Eu(cddadpa)]
−
 recorded in H2O and D2O solutions show the 
5
D0→
7
FJtransitions 
expected for this metal ion, with maxima at 580 (J=0), 593 (J=1), 615 (J=2), 652 (J=3), and 685 nm (J=4) 
(Figure S10, Supporting Information). The emission lifetimes of the 
5
D0 excited state recorded in H2O and 
D2O are 0.58 and 2.15 ms, respectively. These values provide hydration numbers of q=1.20 and 1.05 using 
the methods developed by Beeby
[24] 
and Horrocks,
[25] 
respectively, which points to the presence of one water 
molecule coordinated to the Ln
3+
 ion. 
 
 
The relaxivity (r1p) measured for [Gd(cddadpa)]
−
 at 20 MHz and 25 °C (pH 7.4) amounts to 5.6 mm−1 s−1, a 
value that is ca. 12 % higher than that measured under the same conditions for [Gd(octapa)]−, and ca. 19 % 
higher than those reported for the commercially available contrast agents [Gd(dota)]
−
 and [Gd(dtpa)]
−
 
(Figure 3). The relaxivity is somewhat lower at 37 °C (4.5 mm−1 s−1), which indicates that it is limited by fast 
rotation. However, the r1p value obtained at 37 °C is still higher than those of [Gd(octapa)]
−
 (3.9 mm
−1 s−1), 
[Gd(dota)]
−
 (3.8 mm
−1 s−1), and [Gd(dtpa)]− (4.0 mm−1 s−1). This is likely related to the rigid nature of 
[Gd(cddadpa)]
−
, which leads to a slightly longer rotational correlation time. 
In conclusion, we have shown that the strained, open-chain ligand cddadpa
4−
 forms a Gd
3+
 complex with 
high thermodynamic stability and unprecedented kinetic inertness for a linear chelate, which becomes 
comparable to those of macrocyclic complexes. The incorporation of the rigid diaminocyclohexane unit does 
not alter the hydration number of the complex and increases slightly its 
1
H relaxivity. Our results highlight 
the importance of rigidification in the ligand backbone to design Gd
3+
-based contrast agents with improved 
features. The [Gd(cddadpa)] complex is a very promising candidate for further development of safer MRI 
contrast agents. 
 
 
Figure 3. Plot of the relaxivity, r1p, for selected Gd
3+
 complexes at 20 MHz and 25 °C (dark gray)  
and 37 °C (light gray). 
 
 
Experimental Section 
General 
Chemicals were purchased from commercial sources and used without further purification. SiO2 (Fluka, pore 
size 60 Å, 70–230 mesh) was used for preparative column chromatography. Compound 3 was synthesized as 
described previously.
[26] 1
H and 
13
C NMR spectra were recorded at 25 °C on Bruker Avance 500 MHz and 
Bruker Avance 300 MHz spectrometers. High-resolution ESI-TOF mass spectra were recorded using a LC-
Q-q-TOF Applied Biosystems QSTAR Elite spectrometer both in the positive and negative modes. 
Elemental analyses were carried out on a ThermoQuest Flash EA 1112 elemental analyzer. IR spectra were 
recorded using a Bruker Vector 22 spectrophotometer equipped with a Golden Gate Attenuated Total 
Reflectance (ATR) accessory (Specac). Excitation and emission spectra were recorded on a PerkinElmer LS-
50B spectrometer. Luminescence lifetimes were calculated from the monoexponential fitting of the average 
 
 
decay data, and they are averages of at least 3–5 independent determinations. Hydrations numbers q were 
obtained using equation (1), where τH2Oand τD2O respectively refer to the measured luminescence decay 
lifetimes (in ms) in water and deuterated water: 
 
   𝑞Eu = 𝐴(
1
𝜏𝐻2𝑂
−
1
𝜏𝐷2𝑂
− 𝐵)    (1) 
 
where A and B are empirical constants that take values of A=1.2 and B=0.25
[23]
 or A=1.11 and B=0.31.
[25]
 
UV/Vis spectra were recorded on a Perkin Elmer Lambda 900 spectrophotometer using a 1.0 cm path quartz 
cell. CD spectra were recorded on a Jasco J-815 circular dichroism spectropolarimeter with a stop-flow 
accessory. 
Equilibrium measurements 
The concentration of the H4cddadpa ligand as well as its protonation constants were determined by using pH-
potentiometric titrations. Methrohm 785 DMP Titrino equipped with a Metrohm 6.0233.100 combined 
electrode was used to measure the pH in titration experiments. For the pH calibration of the electrode, KH-
phthalate (pH 4.005) and borax (pH 9.177) buffers were used. The calculation of [H
+
] from the measured pH 
values was performed with the use of the method proposed by Irving et al.
[27]
 by titrating a 0.01 m HCl 
solution (I=0.15 m NaCl) with a standardized NaOH solution. The differences between the measured and 
calculated pH values were used to obtain the [H
+
] concentrations from the pH-data collected in the titrations. 
The ion product of water was determined (pKw=13.820) from the same experiment in the pH range 11.40–
12.00. The ionic strength in the titrated and thermostated (at 25 °C) samples of 6.00 mL was kept constant 
and set to 0.15 m NaCl. The samples were stirred by a mechanical stirrer and kept under inert gas atmosphere 
(N2) to avoid the effect of CO2. The protonation constants of the ligand were determined by direct pH-
potentiometric titration by titrating 2.28 mm ligand solutions with a standardized NaOH solution in the pH 
range of 1.80–12.00. The protonation constants of the ligand and the stability constant of its Gd3+ complex 
are defined as KHiL=[HiL]/[Hi−1L][H
+
] and KGdL=[GdL]/[Gd
3+
][L]). The determination of the stability 
constant of [Gd(cddadpa)]
−
 complex was carried out using the 
1
H-relaxometric method by measuring the 
longitudinal relaxation times of the samples acquired in a wide pH range (pH 1–12 for the samples with 
pH<1.8, pH=−log cH+). 34 samples were prepared for this purpose containing Gd
3+
 and the cddadpa
4−
ligand 
at 1 mm concentration (I=0.15 m). The samples were equilibrated for one day and their T1relaxation times 
were then recorded. The measurements were performed with a Bruker Minispec MQ20 NMR analyzer (20 
MHz, 25 °C) using the inversion recovery method (180°–τ–90°) at 14 different τ values. The data were fitted 
by using the molar relaxivities of [Gd(cddadpa)]
−
 and Gd
3+
 determined independently (5.73 and 13.27 
mm
−1 s−1 at 25 °C and 20 MHz, respectively) by using previously reported methods. These data were fitted 
simultaneously with the pH-potentiometric titration data for the sample containing equimolar amounts of the 
ligand and Gd
3+
. The protonation and stability constants were calculated from the titration data with the 
PSEQUAD program.
[28] The pGd=−log [Gd]free values of the complexes were calculated by using the 
protonation constants of the ligands and stability constants of the complexes at physiological pH 7.4 using 10 
μm ligand and 1 μm Gd3+ ion concentrations, as suggested by Raymond and co-workers.[20] 
Kinetic measurements 
The rates of the metal exchange reactions involving the [Gd(cddadpa)]
−
 complex and the Cu
2+
 ion were 
studied by using UV/Vis spectrophotometry following the formation of the [Cu2(cddadpa)] complex. The 
conventional UV/Vis spectroscopic method was applied to follow the decomplexation reactions of 
 
 
[Gd(cddadpa)]
−
 as these reactions were very slow even at relatively low pH. The absorbance vs. time kinetic 
curves were acquired by using a Jasco V-670 UV/Vis spectrophotometer equipped with Peltier thermostatted 
multicell holder. The temperature was maintained at 25 °C and the ionic strength of the solutions was kept 
constant by using 0.15 m NaCl. For keeping the pH constant, 50 mmdimethylpiperazine (dmp) buffer was 
used (log K2
H
=4.15 (0.03) as determined by using pH potentiometry). The exchange reactions were followed 
at 310 nm in the pH range 3.38–4.96 for 4–5 days continuously (60–90 % conversion) while absorbance 
readings at equilibrium were determined by allowing the reactions to react for 3–4 weeks depending on the 
pH of the samples (8–10 times longer than the half-life of the reaction). The concentration of the 
[Gd(cddadpa)]
−
 complex was 0.311 mm, while the Cu
2+
 ion was applied at high excess (11.1 to 40.9-fold) 
guarantee pseudo-first order conditions. The absorbance vs. time reaction profiles could perfectly fitted by 
using the monoexponential function (Eq.): 
 
   𝐴t = (𝐴0 − 𝐴e)e
−𝑘obs𝑡 + 𝐴e    (2) 
 
where At, A0, and Ae are the absorbance at time t, at the start, and at equilibrium, respectively. The pseudo-
first-order rate constants were fitted with the computer program Micromath Scientist, version 2.0 (Salt Lake 
City, UT, USA) by using a standard least-squares procedure. 
Dimethyl 6,6′-[{(1 R,2 R)-cyclohexane-1,2-diylbis[{2-(tert-butoxy)-2-oxoethyl}azanediyl]}bis(methylene)] 
dipicolinate (4): A mixture of 3 (1.00 g, 2.42 mmol obtained as described in the Supporting Information) 
and K2CO3 (2.95 g, 21.3 mmol) in acetonitrile (100 mL) was stirred for 30 min, and then tert-butyl-2-
bromoacetate (0.99 g, 5.08 mmol) was added. The mixture was stirred at room temperature for 4 days under 
an inert atmosphere (Ar), and later at 45 °C for a period of 3 days. The excess K2CO3 was filtered off, the 
filtrate was concentrated to dryness, and the yellow oil was extracted with a 1:3 mixture of H2O and 
CHCl3 (200 mL). The organic phase was evaporated to dryness giving an oily residue that was purified by 
column chromatography on SiO2 with a CH2Cl2/MeOH 5 % mixture as the eluent to give 1.01 g of 4 as a 
pale yellow oil. Yield 65 %; 1H NMR (500 MHz, CDCl3, 25 °C, TMS): δ=8.05 (d, 
3
J=7.8 Hz, 2 H), 7.94 
(d, 
3
J=7.8 Hz, 2 H), 7.58 (t, 3J=7.8 Hz, 2 H), 3.98 (s, 6 H), 3.92 (d, 2J=15.1 Hz, 2 H), 3.80 (d, 2J=15.1 Hz, 
2 H), 3.38 (d, 2J=16.8 Hz, 2 H), 3.27 (d, 2J=16.8 Hz, 2 H), 2.64 (m, 2 H), 2.13 (m, 2 H), 1.74 (m, 2 H), 1.43 
(s, 18 H), 1.11 ppm (m, 4 H); 13C NMR (125.8 MHz, CDCl3, 25 °C, TMS): δ=171.3, 166.0, 161.7, 146.7, 
136.9, 127.6, 123.5, 80.4, 61.6, 56.0, 52.8, 52.6, 28.1, 26.2, 25.9 ppm; IR (ATR):  =1721 cm
−1
 (C=O); HR-
MS (ESI
+
, MeOH:CH3CN:H2O 9:1:1): m/zcalcd for [C34H49N4O8]
+
: 641.3544; found: 641.3554; elemental 
analysis calcd (%) for C34H48N4O8: C 63.73, H 7.55, N 8.74; found: C 64.02, H 7.54, N 8.86. 
6,6′-[{(1 R,2 R)-Cyclohexane-1,2-diylbis[(carboxymethyl)azanediyl]}bis(methylene)]dipicolinic acid 
(H4cddadpa⋅3 HCl⋅2 H2O): A solution of compound 4 (1.01 g, 1.58 mmol) in 6 m HCl (50 mL) was heated 
to reflux for 24 h, and then the solvent was removed in a rotary evaporator to give a yellow oil. A small 
amount of H2O was added (ca. 20 mL) and the mixture evaporated to dryness. This process was repeated 
once with addition of H2O and twice with addition of diethyl ether (ca. 20 mL), returning 0.77 g of the 
desired ligand as a dark yellow solid. Yield 75 %; 1H NMR (500 MHz, D2O, pD 2.5, 25 °C, TMS): δ=8.10–
7.86 (m, 6 H), 4.26–3.35 (m, 10 H), 2.22 (m, 2 H), 1.83 (m, 2 H), 1.45 (m, 2 H), 1.29 ppm (m, 2 H); 13C 
NMR (125.8 MHz, D2O, pD 2.5, 25 °C, TMS): δ=171.4, 164.9, 152.3, 145.2, 129.4, 125.7, 125.6, 62.4, 52.7, 
50.5, 23.8 ppm; IR (ATR):  =1714, 1627 cm
−1
 (C=O); MS (ESI
+
, MeOH:CH3CN:H2O 9:1:1): m/z 539 
[C24H28KN4O8]
+
; elemental analysis calcd (%) for C24H28N4O8⋅3 HCl⋅2 H2O: C 44.63, H 5.46, N 8.67; found: 
C 44.46, H 5.41, N 8.49. 
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